Champions Oncology Inc Revenue Growth Rates (CSBR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Champions Oncology Inc   (NASDAQ: CSBR)
 

CSBR's Revenue Growth by Quarter and Year

Champions Oncology Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CSBR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter April -
3rd Quarter January -
2nd Quarter October -
1st Quarter July 15.23
FY 15.23

CSBRs Annual Revenue
Champions Oncology Inc 's Revenue in the fiscal year 2026 $ 59.43 millions
Champions Oncology Inc 's Revenue in the fiscal year 2025 $ 56.94 millions
Champions Oncology Inc 's Revenue in the fiscal year 2024 $ 50.16 millions
Champions Oncology Inc 's Revenue in the fiscal year 2023 $ 53.87 millions
Champions Oncology Inc 's Revenue in the fiscal year 2022 $ 49.11 millions




CSBR Revenue first quarter 2026 Y/Y Growth Comment
Champions Oncology Inc reported Revenue growth of 8.8% year on year in the first quarter 2026, to $ 15.23 millions, this is lower than Champions Oncology Inc 's recent average Revenue increase of 16.79%.

Looking into first quarter 2026 results within Biotechnology & Pharmaceuticals industry 48 other companies have achieved higher Revenue growth. While Champions Oncology Inc ' s Revenue increase of 8.8% ranks overall at the positon no. 2992 in the first quarter 2026.


CSBR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter April - 11.97 % -11.71 % 7.12 %
3rd Quarter January - -2.82 % 41.76 % -5.87 %
2nd Quarter October - 11.49 % 16.59 % -18.98 %
1st Quarter July 8.8 % -0.43 % 11.94 % -8.65 %
FY   - 4.37 % 13.56 % -

Financial Statements
Champions Oncology Inc 's first quarter 2026 Revenue $ 15.23 millions CSBR's Income Statement
Champions Oncology Inc 's first quarter 2025 Revenue $ 14.00 millions Quarterly CSBR's Income Statement


CSBR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter April - -16.43 % -27.46 % 16.47 %
3rd Quarter January - 10.11 % 26.32 % 3.89 %
2nd Quarter October - 7.43 % -4.05 % -7.88 %
1st Quarter July 10.06 % 13.27 % 0.43 % -3.9 %
FY (Year on Year)   - 4.37 % 13.56 % -


Back to CSBR Growth rate Comparisons >> Back to CSBR Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #49
Healthcare Sector #409
Overall #2992

Revenue Y/Y Growth Statistics
High Average Low
43.38 % 16.79 % -26.11 %
(Jan 31 2016)   (Jan 31 2015)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #49
Healthcare Sector #409
Overall #2992
Revenue Y/Y Growth Statistics
High Average Low
43.38 % 16.79 % -26.11 %
(Jan 31 2016)   (Jan 31 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Champions Oncology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
200.64 % 6.45 % -100 %
(Jan 31 2011)  


CSBR's I. Quarter Q/Q Revenue Comment
Champions Oncology Inc achieved in the I. Quarter 2026 above company average sequential Revenue rise of 10.06%, to $ 15.23 millions, from $13.84 millions in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry 33 other companies have achieved higher Revenue quarter on quarter growth. While Champions Oncology Inc 's Revenue growth quarter on quarter, overall rank is 1129.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #34
Healthcare Sector #257
Overall #1129
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #34
Healthcare Sector #257
Overall #1129
Revenue Q/Q Growth Statistics
High Average Low
200.64 % 6.45 % -100 %
(Jan 31 2011)  


CSBR's I. Quarter Q/Q Revenue Comment
Champions Oncology Inc achieved in the I. Quarter 2026 above company average sequential Revenue rise of 10.06%, to $ 15.23 millions, from $13.84 millions in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry 33 other companies have achieved higher Revenue quarter on quarter growth. While Champions Oncology Inc 's Revenue growth quarter on quarter, overall rank is 1129.


Champions Oncology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jul 31 2026)		 12 Months Ending
(Apr 30 2026)		 12 Months Ending
(Jan 31 2026)		 12 Months Ending
(Oct 31 2025)		 12 Months Ending
(Jul 31 2025)
Cumulative Revenue 12 Months Ending $ 60.66 $ 59.43 $ 57.94 $ 58.42 $ 56.88
Y / Y Revenue Growth (TTM) 6.65 % 4.36 % -1.1 % 9.06 % 10.11 %
Year on Year Revenue Growth Overall Ranking # 1672 # 1249 # 580 # 1403 # 2206
Seqeuential Revenue Change (TTM) 2.08 % 2.56 % -0.82 % 2.72 % -0.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 2992 # 3059 # 1134 # 1778 # 1745


Cumulative Revenue growth Comment
Although Champions Oncology Inc 's Annual Revenue growth year on year were below company's average 16.79% , Revenue announced in the Jul 31 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6.65% year on year, from 4.36% in Apr 30 2026.

In the Healthcare sector 276 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1249 to 1672.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 49
Healthcare Sector # 277
Overall # 1672

Revenue TTM Y/Y Growth Statistics
High Average Low
43.38 %
 16.79 %
-26.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 409
S&P 500 # 2992
Cumulative Revenue growth Comment
Although Champions Oncology Inc 's Annual Revenue growth year on year were below company's average 16.79% , Revenue announced in the Jul 31 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6.65% year on year, from 4.36% in Apr 30 2026.

In the Healthcare sector 276 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1249 to 1672.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 49
Healthcare Sector # 277
Overall # 1672

Revenue TTM Y/Y Growth Statistics
High Average Low
43.38 %
16.79 %
-26.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 409
S&P 500 # 2992




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CSBR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jul 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jul 31 2026
Medtronic Plc13.73%$ 13.733 millions
Exelixis Inc 10.63%$ 10.634 millions
Heartsciences Inc 10.53%$ 10.526 millions
Champions Oncology Inc 8.84%$ 8.839 millions
Agilent Technologies inc 8.06%$ 8.055 millions


About Champions Oncology Inc Revenue Growth Rates (CSBR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Champions Oncology Inc (CIK 771856).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-061519
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Champions Oncology Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.